Oura, smart ring maker, confidentially files for IPO

Oura confidentially filed for an IPO after reporting it is on track to surpass 5 million paid members this quarter, with revenue up 4x over the past two fiscal years. The smart-ring maker was last valued at $11 billion after a $900 million Series E round and has raised more than $1.5 billion in total. The filing adds another notable consumer-health tech name to an improving U.S. IPO pipeline, though timing remains contingent on SEC review and market conditions.

Analysis

Oura’s filing is less a single-company event than a read-through on the monetization curve for consumer health wearables. The market is likely to treat this as validation that subscription-like health data businesses can move from novelty hardware to recurring revenue platforms, which should support multiples across the category—especially where device economics are coupled to software/analytics attach. The more important second-order effect is that the real competitive battleground shifts from sensor quality to data utility: whoever can convert passive tracking into habit-forming, decision-grade insights will defend pricing power.

For the public comps, the implication is not symmetric. Garmin should be the cleaner beneficiary if investors rotate into advanced wearables exposure because it has a broader distribution footprint and a more established cash-flow profile; Oura’s IPO would expand the category’s TAM narrative without forcing Garmin to prove a pure-consumer subscription model. Apple is the more subtle loser: every high-profile health wearable IPO reinforces that dedicated devices can still out-own specific use cases that the Watch has not fully monopolized, which modestly caps the “health moat” premium in AAPL rather than driving an immediate earnings impact. Google/Fitbit is the most vulnerable strategically, because a screenless, insight-first product resets the bar for simplicity and may make Fitbit look incrementally less differentiated at the premium end.

The key risk is that the IPO window itself becomes the catalyst for investor scrutiny of retention and engagement quality rather than top-line growth. If the filing surfaces any slowing paid-member additions, elevated CAC, or hardware subsidy pressure, the market will quickly re-rate the group from “category winner” to “consumer hardware with a software multiple,” which can unwind in days. Over a 6-12 month horizon, the bigger watch item is whether Apple and Google respond with bundled health features that compress willingness to pay for standalone devices.

Consensus may be underestimating the partnership angle: distribution through insurers, employers, sports leagues, and wellness platforms can become the real growth engine, and that model scales far better than direct-to-consumer hardware alone. That makes the key question for the IPO not just revenue growth, but gross margin durability and the share of sales coming from ecosystem-driven channels versus paid media. If those metrics are strong, the stock could support a scarcity premium; if not, the IPO could become a high-profile cap on category valuations rather than a launchpad.

Key Decisions for Investors

• Long GRMN vs. AAPL into the IPO window: favor Garmin as the cleaner public beneficiary of renewed advanced-wearables enthusiasm; target a 3-6 month horizon with tighter downside risk than a direct long in the category. Use AAPL as the hedge because the event reinforces standalone health-device differentiation, which can modestly dilute Watch premium narrative.
• Buy GOOGL on weakness only, not strength: the screenless Fitbit launch makes Google a potential strategic beneficiary if it can re-accelerate device engagement, but the trade is higher risk because execution is unclear. Use a 1-3 month view and keep sizing small; the upside is improved perception around consumer health, but the risk is another product that fails to establish daily habit formation.
• Avoid chasing OURA-related pre-IPO hype in public comps; instead, sell volatility in the most stretched health-wearables names after filing-driven spikes. The base case is sentiment-driven multiple expansion first, fundamentals later, so premium calls can offer better risk/reward than outright longs if liquidity is rich.
• If Oura’s prospectus confirms strong recurring revenue mix and low churn, rotate into a basket long of GRMN / GOOGL against AAPL. This is a 6-12 month relative-value expression on category fragmentation, where specialized health devices and platform extensions can outperform the mature generalist.
• Watch for a post-filing dip in AAPL implied volatility around any event-related health-news premium; if the market overprices competitive threat, selling near-dated downside protection can monetize the overreaction while maintaining core exposure.